Addendum

Dolutegravir/lamivudine (HIV infection) - Addendum to Commission A19-55

Status
Status: Commission completed
Project no.
A19-102
Last updated

Report documents

  1. Addendum

    Dolutegravir/lamivudine (HIV infection) - Addendum to Commission A19-55

    published on
    Document type
    PDF document, 334 kB, DE, not accessible

Dossier assessment

Indication:

Adults with HIV-1 infection whose virus has no known or suspected resistance to integrase inhibitors or lamivudine

Result of dossier assessment:

Now proof of considerable (before: minor) added benefit for treatment-naive adults with HIV-1 infection

Additional information

Federal Joint Committee (G-BA)

2020-02-06 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A19-102
Commission
Commission awarded on 09.12.2019 by the Federal Joint Committee (GBA).
Report type
Addendum
Status
Commission completed
Department/Division
Drug Assessment
Topic
Immune system and infections
Note

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Connected Projects

  1. Addendum

    Dolutegravir/lamivudine (HIV infection) - Second Addendum to Commission A19-55

    Project no.
    A19-103
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Dolutegravir/lamivudine (HIV infection) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-55
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form